Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind double-dummy multicenter study of WXFL10203614 tablets in moderate-to-severe active rheumatoid arthritis
CTR20231989Phase 3Active
- Sponsor
- Wuxi Fuxin Pharmaceutical
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of WXFL10203614 in rheumatoid arthritis (RA), sponsored by Wuxi Fuxin Pharmaceutical. Started Sep 2023; status: active.
02
Drugs
WXFL10203614
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20231989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231989.